Anzeige
Mehr »
Donnerstag, 26.06.2025 - Börsentäglich über 12.000 News
TAO +1.800?%, SBAR +85?%, CYK +280?% - jetzt startet KORA auf Unternehmensebene durch!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EQWL | ISIN: US60458C1045 | Ticker-Symbol: K6S
Frankfurt
25.06.25 | 15:29
1,090 Euro
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
MIRA PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
MIRA PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,0501,09025.06.

Aktuelle News zur MIRA PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiMIRA Pharmaceuticals Announces New Data Underscoring Potential of SKNY-1 - A Drug Candidate Pending Acquisition - To Disrupt Weight Loss and Smoking Cessation Markets Without CNS Side Effects80MIAMI, FL / ACCESS Newswire / June 25, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapeutics for...
► Artikel lesen
DiMIRA PHARMACEUTICALS, INC. - 8-K, Current Report1
18.06.MIRA Pharmaceuticals' ketamine analog accepted for publication3
18.06.MIRA Pharmaceuticals' Lead Drug Candidate Ketamir-2 First Manuscript Accepted for Publication in the Peer-Reviewed Journal Frontiers in Pharmacology338MIAMI, FL / ACCESS Newswire / June 18, 2025 / MIRA Pharmaceuticals, Inc. (Nasdaq:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company developing novel therapeutics for neurologic...
► Artikel lesen
MIRA PHARMACEUTICALS Aktie jetzt für 0€ handeln
17.06.MIRA PHARMACEUTICALS, INC. - 8-K, Current Report3
28.05.MIRA Pharmaceuticals to Participate in BIO 2025 in Boston and Highlights Ongoing Progress Across Clinical Program230The company will engage in BIO One-on-One Partnering meetings as it advances Phase 1 for Ketamir-2, prepares Phase IIa study in neuropathic pain, and finalizes filings for SKNY acquisition. MIAMI, FL...
► Artikel lesen
28.05.MIRA Pharmaceuticals gibt klinische Fortschritte und Akquisitionsupdate bekannt4
21.05.MIRA PHARMACEUTICALS, INC. - 8-K, Current Report1
14.05.MIRA PHARMACEUTICALS, INC. - 10-Q, Quarterly Report8
08.05.MIRA Pharmaceuticals board approves SKNY Pharmaceuticals acquisition; combined value tops $60M8
08.05.MIRA Pharmaceuticals erwirbt SKNY in strategischem Schritt4
08.05.MIRA Pharmaceuticals to acquire SKNY in strategic move3
08.05.MIRA Pharmaceuticals Announces Board Approval of SKNY Acquisition Reflecting $60+ Million in Combined Enterprise Value Based on Independent Review507With valuations confirmed by the board, MIRA advances strategic acquisition targeting obesity and nicotine dependence, which includes a $5 million contribution in cash or assets from SKNY to be transferred...
► Artikel lesen
08.05.EXCLUSIVE: Mira Pharmaceuticals Board Approves SKNY Pharma Acquisition, Establishing Combined Enterprise Value Over $60 Million5
06.05.MIRA Pharmaceuticals berichtet über sicheres Profil für Ketamir-29
06.05.MIRA Pharmaceuticals Reports No Brain Toxicity in FDA-Required Study of Ketamir-2, Confirming Absence of Ketamine-Linked Neurotoxicity130Preclinical data supports the advancement of oral Ketamir-2 as a safe, next-generation alternative to ketamine, with ongoing momentum in Phase I clinical trial enrollment MIAMI, FL / ACCESS Newswire...
► Artikel lesen
06.05.MIRA PHARMACEUTICALS, INC. - 8-K, Current Report4
06.05.EXCLUSIVE: MIRA Pharmaceuticals Lead Program Ketamir-2 Shows No Brain Toxicity In FDA-Mandated Study4
23.04.MIRA Pharmaceuticals reports positive in vitro drug release data for topical Ketamir-21
23.04.MIRA Pharmaceuticals Reports Positive In Vitro Drug Release Data for Topical Ketamir-2, Targeting $11B+ U.S. Topical Pain Relief Market and Exploring FDA Fast Track Designation161MIAMI, FLORIDA / ACCESS Newswire / April 23, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), or MIRA, a clinical-stage pharmaceutical company focused on developing novel therapeutics for neurologic...
► Artikel lesen
Weiter >>
56 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1